Dose-related effects of lauric acid on antropyloroduodenal motility, gastrointestinal hormone release, appetite, and energy intake in healthy men.
We recently reported that intraduodenal infusion of lauric acid (C12) (0.375 kcal/min, 106 mM) stimulates isolated pyloric pressure waves (IPPWs), inhibits antral and duodenal pressure waves (PWs), stimulates release of cholecystokinin (CCK) and glucagon-like peptide-1 (GLP-1), and suppresses energy intake and that these effects are much greater than those seen in response to isocaloric decanoic acid (C10) infusion. Administration of C12 was, however, associated with nausea, confounding interpretation of the results. The aim of this study was to evaluate the effects of different intraduodenal doses of C12 on antropyloroduodenal (APD) motility, plasma CCK and GLP-1 concentrations, appetite, and energy intake. Thirteen healthy males were studied on 4 days in double-blind, randomized fashion. APD pressures, plasma CCK and GLP-1 concentrations, and appetite perceptions were measured during 90-min ID infusion of C12 at 0.1 (14 mM), 0.2 (28 mM), or 0.4 (56 mM) kcal/min or saline (control; rate 4 ml/min). Energy intake was determined at a buffet meal immediately following infusion. C12 dose-dependently stimulated IPPWs, decreased antral and duodenal motility, and stimulated secretion of CCK and GLP-1 (r > 0.4, P < 0.05 for all). C12 (0.4 kcal/min) suppressed energy intake compared with control, C12 (0.1 kcal/min), and C12 (0.2 kcal/min) (P < 0.05). These effects were observed in the absence of nausea. In conclusion, intraduodenal C12 dose-dependently modulated APD motility and gastrointestinal hormone release in healthy male subjects, whereas effects on energy intake were only apparent with the highest dose infused (0.4 kcal/min), possibly because only at this dose was modulation of APD motility and gastrointestinal hormone secretion sufficient for a suppressant effect on energy intake.
Little
Tanya J
TJ
Department of Medicine, Royal Adelaide Hospital, North Terrace, Adelaide SA 5000, Australia.
Feltrin
Kate L
KL
Horowitz
Michael
M
Smout
Andre J P M
AJ
Rades
Thomas
T
Meyer
James H
JH
Pilichiewicz
Amelia N
AN
Wishart
Judith
J
Feinle-Bisset
Christine
C
D000328:Adult; D001066:Appetite / Q000187:drug effects* / Q000502:physiology; D002766:Cholecystokinin / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004386:Duodenum / Q000187:drug effects / Q000378:metabolism*; D002149:Energy Intake / Q000187:drug effects* / Q000502:physiology; D004750:Enteral Nutrition; D005768:Gastrointestinal Hormones / Q000097:blood; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology*; D005934:Glucagon / Q000097:blood*; D052216:Glucagon-Like Peptide 1; D006801:Humans; D007850:Lauric Acids / Q000008:administration & dosage*; D008297:Male; D010446:Peptide Fragments / Q000097:blood*; D011498:Protein Precursors / Q000097:blood*; D011706:Pyloric Antrum / Q000187:drug effects / Q000378:metabolism*; D011708:Pylorus / Q000187:drug effects / Q000378:metabolism
D005768:Gastrointestinal Hormones; D007850:Lauric Acids; D010446:Peptide Fragments; D011498:Protein Precursors; C030358:lauric acid; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D002766:Cholecystokinin